# Junshi Biosciences Completes First Patient Dosing for HCC Trial

> Junshi Biosciences completes first patient dosing in phase 3 trial for advanced liver cancer treatment.
- Title: Junshi Biosciences Completes First Patient Dosing for HCC…
- Summary: Junshi Biosciences completes first patient dosing in phase 3 trial for advanced liver cancer treatment. Junshi Biosciences completed first patient dosing in…
- Keywords: junshi biosciences, js207, js007, hepatocellular carcinoma, phase 3 clinical trial, advanced liver cancer, recombinant humanized anti-pd-1/vegf bis, recombinant humanized anti-ctla-4 monocl, money, business, Junshi, Biosciences
- Source: Financialpost — https://financialpost.com/globe-newswire/junshi-biosciences-announces-the-completion-of-first-patient-dosing-in-the-phase-3-clinical-trial-of-js207-in-combination-with-js007-for-the-first-line-treatment-of-advanced-hepatocellular-carcinoma
- Read time: 1 min
- Topics: junshi biosciences, js207, js007, hepatocellular carcinoma, phase 3 clinical trial, advanced liver cancer, recombinant humanized anti-pd-1/vegf bis, recombinant humanized anti-ctla-4 monocl, money, business
## Junshi Biosciences Announces Trial Completion
Shanghai Junshi Biosciences Co., Ltd announced completion of first patient dosing in a phase 3 clinical trial for advanced hepatocellular carcinoma treatment.
## Hepatocellular Carcinoma Burden in China
China accounts for approximately 354,100 new liver cancer cases and 303,800 deaths in 2024, making it the second leading cause of cancer-related death after lung cancer.
## Current Treatment Limitations
Current first-line systemic therapies for intermediate and advanced liver cancer have median overall survival less than 2 years.
## Phase 2 Results Presented at ESMO 2026
JS207 in combination with JS007 showed 44.1% objective response rate and 85.3% disease control rate in phase 2 study.
## Phase 3 Study Design
JS207-017-III-HCC study plans to enroll 560 subjects comparing JS207+JS007 to toripalimab+bevacizumab for first-line advanced hepatocellular carcinoma.
## JS207 Mechanism of Action
JS207 simultaneously binds to PD-1 and VEGFA to block tumor growth and improve immune response.
## Next Steps for Treatment
The phase 3 trial will assess progression-free survival and overall survival for advanced hepatocellular carcinoma patients.
## Key takeaway

Junshi Biosciences completed first patient dosing in phase 3 trial for advanced hepatocellular carcinoma treatment using JS207 and JS007 combination therapy.